Tildrakizumab-asmn

Brand names: Ilumya · Active ingredient: Tildrakizumab

In short: ILUMYA® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ILUMYA is indicated for the treatment of active psoriatic arthritis in adult patients.

Forms & strengthsInjection: 100 mg/mL solution in a single-dose prefilled syringe. ILUMYA is a clear to slightly opalescent, colorless to slightly yellow solution.
LabelSun Pharmaceutical Industries, Inc.
Label updatedNov 03, 2026

What is Tildrakizumab-asmn used for?

ILUMYA® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

ILUMYA is indicated for the treatment of active psoriatic arthritis in adult patients.

Tildrakizumab-asmn dosage

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA .

Consider completion of all age appropriate immunizations according to current immunization guidelines.

Administer ILUMYA as a subcutaneous injection.

Moderate-to-Severe Plaque Psoriasis

The recommended dosage in adult patients with moderate-to-severe plaque psoriasis is 100 mg at Weeks 0, 4, and every 12 weeks thereafter.

Active Psoriatic Arthritis

For adult patients with active psoriatic arthritis and coexistent moderate-to-severe plaque psoriasis, the recommended dosage is the same as in adults with moderate-to-severe plaque psoriasis.

For other adult patients with active psoriatic arthritis, the recommended dosage is 100 mg every 12 weeks.

ILUMYA should only be administered by a healthcare provider. Administer ILUMYA subcutaneously. Each prefilled syringe is for single-dose only. Inject the full amount (1 mL), which provides 100 mg of tildrakizumab per syringe. If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regularly scheduled interval.

Before injection, remove ILUMYA carton from the refrigerator, and let the prefilled syringe (in the ILUMYA carton with the lid closed) sit at room temperature for 30 minutes.

Follow the instructions on the ILUMYA carton to remove the prefilled syringe correctly, and remove only when ready to inject. Do not pull off the needle cover until you are ready to inject.

Inspect ILUMYA visually for particulate matter and discoloration prior to administration. ILUMYA is a clear to slightly opalescent, colorless to slightly yellow solution. Do not use if the liquid contains visible particles or the syringe is damaged. Air bubbles may be present; there is no need to remove them.

Choose an injection site with clear skin and easy access (such as abdomen, thighs, or upper arm). Do not administer 2 inches around the navel or where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis. Also, do not inject into scars, stretch marks, or blood vessels.

While holding the body of the syringe, pull the needle cover straight off (do not twist) and discard.

Inject ILUMYA subcutaneously as recommended .

Press down the blue plunger until it can go no further. This activates the safety mechanism that will ensure full retraction of the needle after the injection is given.

Remove the needle from the skin entirely before letting go of the blue plunger. After the blue plunger is released, the safety lock will draw the needle inside the needle guard.

Discard any unused portion. Dispose of used syringe.

How to take Tildrakizumab-asmn — instructions & advice from the label

Advise patients and/or caregivers to read the FDA-approved patient labeling (Medication Guide).

Instruct patients and/or caregivers to read the Medication Guide before starting ILUMYA therapy and to reread the Medication Guide each time the prescription is renewed. Advise patients of the potential benefits and risks of ILUMYA.

Hypersensitivity

Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions .

Infections

Instruct patients of the importance of communicating any history of infections to the doctor and contacting their doctor if they develop any symptoms of infection .

Immunizations

Instruct patients to inform the healthcare practitioner that they are taking ILUMYA prior to a potential vaccination since the use of live vaccine is not recommended .

Pregnancy

Advise patients that there is a pregnancy registry that monitors pregnancy outcomes in women exposed to ILUMYA during pregnancy .

Manufactured by: Sun Pharmaceutical Industries Limited

Mumbai, Maharashtra India 400 063

U.S. License No. 2092Tildrakizumab-asmn (active ingred.) Product of South Korea.

Distributed by: Sun Pharmaceutical Industries, Inc. …

Warnings & precautions

Do not take this medicine if: ILUMYA is contraindicated in patients with a history of serious hypersensitivity reaction to tildrakizumab or to any of the excipients .

Cases of angioedema and urticaria occurred in ILUMYA treated subjects in clinical trials. If a serious hypersensitivity reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy .

ILUMYA may increase the risk of infection. In subjects with plaque psoriasis, although infections were more common in the ILUMYA group (23%), the difference in frequency of infections between the ILUMYA group and the placebo group (22%) was less than 1% during the placebo-controlled period. However, subjects with active infections or a history of recurrent infections were not included in clinical trials. Upper respiratory infections occurred more frequently in the ILUMYA group than in the placebo group .

In subjects with plaque psoriasis, the rates of serious infections for the ILUMYA group and the placebo group were ≤0.3%.

In subjects with psoriatic arthritis, infections were more common in the ILUMYA 100 mg group (31%) than in the placebo group (28%) during the 24-week placebo-controlled period. The rates of serious infections for the ILUMYA group and the placebo group were 0.4% and 0%, respectively.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing ILUMYA. Instruct patients to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection or is not responding to standard therapy, monitor the patient closely and consider discontinuation of ILUMYA until the infection resolves .

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. …

Tildrakizumab-asmn side effects

The following serious adverse reactions are discussed elsewhere in the labeling:

Hypersensitivity Reactions

Infections

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Plaque Psoriasis

In clinical trials, a total of 1994 subjects with plaque psoriasis were treated with ILUMYA, of which 1083 subjects were treated with ILUMYA 100 mg. Of these, 672 subjects were exposed for at least 12 months, 587 for 18 months, and 469 for 24 months.

Data from three placebo-controlled trials (Trials 1, 2, and 3) in 705 subjects (mean age 46 years, 71% males, 81% white) were pooled to evaluate the safety of ILUMYA (100 mg administered subcutaneously at Weeks 0 and 4, followed by every 12 weeks [Q12W]) .

Placebo-Controlled Period (Weeks 0-16 of Trial 1 and Weeks 0-12 of Trials 2 and 3)

Table 1 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the ILUMYA group than in the placebo group.

Table 1:

Adverse Reactions Occurring in ≥1% of Subjects in the

ILUMYA

Group and More Frequently than in the Placebo Group in the Plaque Psoriasis Trials 1, 2, and 3

* Upper respiratory infections include nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, and pharyngitis. …

About this medicine

Tildrakizumab-asmn is a humanized IgG1/k antibody that specifically binds to the p19 subunit of interleukin-23 (IL-23).

Tildrakizumab-asmn is produced in a recombinant Chinese hamster ovary (CHO) cell line and has an approximate molecular mass of 147 kilodaltons.

ILUMYA (tildrakizumab-asmn) injection, for subcutaneous use, is a sterile, clear to slightly opalescent, colorless to slightly yellow solution. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle.

The syringe is fitted with a passive needle guard and a needle cover.

Each 1 mL single-dose prefilled syringe contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3.

How it works: Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c6a322bb-51b9-4f0e-8642-62a9682ffcde. Read the full official label on DailyMed.

Related medicines

Doxycycline Adalimumab Ketoconazole Levocetirizine Cyclosporine Tretinoin Brimonidine Dupilumab